CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 6 enrolled
Drug / intervention
LY3009104drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01299285
NCT01299285Phase 1Completed
CompareCT.gov

Disposition of 14C-LY3009104 Following Oral Administration in Healthy Human Male Subjects

Eli Lilly and Company·interventional·Posted Feb 18, 2011·Updated Jun 8, 2017

In Brief

A Phase 1 clinical trial evaluating LY3009104 for Healthy Volunteers. Completed, enrolled 6 participants across 1 site.

Detailed Summary

This is a single dose study of radiolabeled \[14C\]-LY3009104 in healthy male volunteers to study the absorption, distribution, metabolism, and elimination of LY3009104. This study requires minimum of 7 days and maximum of 22 days stay. This study is for research purposes only and is not intended to treat any medical condition.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 18, 2011
Enrollment StartFeb 1, 2011
Primary CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 15.4 years ago

Interventions

LY3009104drug

Administered orally